Hematologic Oncology | Specialty

Time Frame for Development of TA-TMA

March 25th 2021

The expert panel considers the time frame of transplant-associated thrombotic microangiopathy, the subtle signs to pay attention to, and testing for proteinuria.

Criteria for Diagnosing TA-TMA

March 25th 2021

A panel of experts in hematopoietic stem cell transplantation examine their personal experience in the incidence of transplant-associated thrombotic microangiopathy in the adult and pediatric populations and the criteria used to diagnose.

Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis

March 24th 2021

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Goals in Treating Low-Risk Primary Myelofibrosis

March 24th 2021

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic. 

A Cardiologist Shares Important Insights Into the Diagnosis and Treatment of Amyloidosis

March 22nd 2021

The 3 most common types of amyloidosis––TTR mutant, TTR wild-type, and amyloid light chain––have a significant amount of cardiac involvement, making cardiologists essential players in the diagnostic workup and treatment of these patients

EZH2 Inhibition in R/R FL: Safety & Efficacy Data

March 22nd 2021

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Tazemetostat for R/R Follicular Lymphoma

March 22nd 2021

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

Novel Therapeutics Target Epigenetic Regulation, Immune System to Boost Activity in AML

March 20th 2021

Kira Gritsman, MD, PhD, discusses several novel agents that are under investigation to improve outcomes in poor-prognosis subsets of patients with AML, early data supporting these approaches, and the potential impact of these options on the treatment paradigm.

Dr. Herrera on Camidanlumab Tesirine in Relapsed/Refractory Hodgkin Lymphoma

March 19th 2021

Alex Herrera, MD, discusses the potential role of camidanlumab tesirine in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial.

Dr. Martin on Selecting Among FDA-Approved BTK Inhibitors in MCL

March 19th 2021

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Dr. Abu-Zeinah on Investigating Interferon-Alpha in Polycythemia Vera

March 19th 2021

Ghaith Abu-Zeinah, MD, discusses utilizing interferon-alpha in patients with polycythemia vera.

Treating Primary Refractory DLBCL

March 19th 2021

Bridging Therapy in R/R DLBCL

March 19th 2021

Promises and Pitfalls of MRD as a Potential Surrogate End Point in AML

March 18th 2021

Jerald Radich, MD, highlights the role minimal residual disease in acute myeloid leukemia, how different technological advanced have increased the application of MRD-based strategies, and ongoing efforts that are being made to address remaining questions.

New CAR T-Cell Therapy Approvals Diversify Treatment Options in Large B-Cell Lymphoma

March 18th 2021

Matthew Lunning, DO, discusses discussed the findings from pivotal CAR T-cell therapy trials in LBCL, the potential to utilize these agents in the outpatient setting, how off-the-shelf allogeneic products could further transform outcomes, and the importance of shortening brain-to-vein time for this patient population.

Incidence of TA-TMA

March 18th 2021

Parameswaran Hari, MD, reviews challenges in defining the incidence of transplant-associated thrombotic microangiopathy; an expert panel comments on the volume of autologous transplants performed in expert centers.

Overview of Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

March 18th 2021

Jeffrey Laurence, MD, provides an overview of transplant-associated thrombotic microangiopathy (TA-TMA), the associated risk factors, and the role of the complement pathway in TA-TMA development.

Dr. Stone on the Promise of Menin Inhibitors in AML

March 17th 2021

Richard M. Stone, MD, discusses the promise of menin inhibitors in patients with acute myeloid leukemia.

Dr. Majhail on the Importance of Utilizing Social Media in Oncology

March 17th 2021

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.

Dr. Cutler on the Toxicity Profile of Belumosudil in cGVHD

March 17th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.